Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant icotinib for high-risk stage IA EGFR-positive NSCLC after complete resection
ChiCTR2400088956Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adjuvant icotinib with Observation (2 arms). Primary endpoint: 3-year disease-free survival rate. Started Aug 2024; status: recruiting.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400088956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088956.